Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Higher Corticosteroid Peak Dose May Worsen Survival in Patients With Treatment-Related Adverse Events

      August 28, 2024
      By Spencer Feldman
      Fact checked by Darlene Dobkowski, MA
      News
      Article

      Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

      Higher Corticosteroid Peak Dose May Worsen Survival in Patients With Treatment-Related Adverse Events

      Higher Corticosteroid Peak Dose May Worsen Survival in Patients With Treatment-Related Adverse Events

      Patients who received higher corticosteroid peak dose for treatment-related adverse events (trAEs) upon treatment with anti-PD-1 and anti-CTLA-4 therapy had worse survival across tumor sites, although this association was not observed with a cumulative dose, recent study findings demonstrated.

      The results from a study published in the Journal of Clinical Oncology may suggest a reconsideration of the starting dose for corticosteroids.

      “Current guidelines recommend a stepdown approach for corticosteroids, advising 1-2 mg/kg prednisone for many grade 3 or higher irAEs,” the study authors wrote. “These data argue for a reconsideration of irAE management approaches. Although prompt immunosuppression is needed to prevent chronicity and fatality in some cases, clinicians should consider starting with lower corticosteroid doses whenever possible.”

      A post hoc analysis was performed using data from 6 phases II/III trials. The analysis included data from 834 patients treated with immunosuppression for trAEs. All patients received corticosteroids and 81 patients received second-line immunosuppressants.

      Patients who received high corticosteroid peak dose typically had worse progression-free survival. In particular, the adjusted HR was 1.15 for 1 mg/kg vs 0.5 mg/kg of prednisone (95% CI, 1.02-1.29; 95% PI, 1.07-1.24); 1.43 for 2.0 mg/kg vs 0.5 mg/kg (95% CI, 1.05-1.96; 95% PI, 1.17-1.75); and 1.25 for 2.0 mg/kg vs 1.0 mg/kg (95% CI, 1.03-1.52; 95% PI, 1.10-1.41).

      Similarly, OS rates were also impaired during higher corticosteroid peak doses of 1.0 vs 0.5 mg/kg, 2.0 vs 0.5 mg/kg, and 2.0 vs 1.0 mg/kg. In particular, adjusted HRs were 1.21 (95% CI, 1.06-1.39; 95% PI, 1.08-1.37); 1.66 (95% CI, 1.17-2.37; 95% PI, 1.23-2.24); and 1.37 (95% CI, 1.10-1.70; 95% PI, 1.14-1.64), respectively.

      Researchers also noted that cumulative corticosteroid dose was not linked with survival. Regarding the use of second-line immunosuppression, the adjusted HR was 1.23 (95% CI, 0.90-1.68) for progression-free survival and 1.25 (95% CI, 0.88-1.77) for overall survival.

      The analysis included 1959 patients (73% male; mean age, 62 years) who received at least 1 dose of anti-PD-1 plus anti-CTLA-4. Patients included in this analysis had different cancer types such as melanoma (n = 313), microsatellite instability high or mismatch repair deficient colorectal cancer (n = 119), advanced renal cell carcinoma (n = 547), advanced esophageal squamous cell carcinoma (n = 322), malignant pleural mesothelioma (n = 300), and metastatic non-small cell lung cancer (n = 358). Follow-up was conducted for a median of 24 months since treatment with anti-PD-1 and anti-CTLA-4 was initiated.

      Most trAEs (77%) occurred within the first 4 months of treatment, and 43% of patients receiving anti-PD-1 plus anti-CTLA-4 therapy experienced trAEs requiring systemic immunosuppression. Most common types of trAE requiring immunosuppression were gastrointestinal (n = 217; 11%), endocrine (n = 161; 8%), hepatobiliary (n = 163; 8%), cutaneous (n = 126; 6%), and pulmonary events (n = 133; 6%). Two percent of patients (n = 16) died from their first trAE.

      The primary outcomes of the trial were overall survival, as defined as the time from starting first immunosuppressant for trAE until death, and progression-free survival, as defined as the time from starting immunosuppression until investigator-reported progressive disease or death due to any cause.

      Findings from the post hoc analysis may not fully reflect real-world practice due to differences in treatment algorithms, and between clinical practice and clinical trial settings. Despite these limitations, the study’s findings are consistent with real-world observations, suggesting their broader use of corticosteroids.

      Reference

      Verheijden RJ, de Groot JS, Fabriek BO, Hew MN, May AM, Suijkerbuijk KPM. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials. J Clin Oncol. Published online August 7, 2024. doi:10.1200/JCO.24.00191

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      4 experts in this video
      4 experts in this video
      Photo of a man wearing glasses and a suit in front of a blue background
      4 experts in this video
      4 experts in this video
      Photo of Hope Rugo, MD
      Image of a woman with blond hair in front of a dark blue background
      Photo of a woman smiling in front of a dark blue background
      4 experts in this video
      4 experts in this video
      Related Content

      Graphic of a person with tumors in their right lung

      ZEN-3694 Receives FDA Fast Track Status in Metastatic NUT Carcinoma

      Russ Conroy
      July 23rd 2025
      Article

      The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      Photo of a healthcare worker holding an x-ray of lungs with tumors

      Tarlatamab Yields Response in Real-World ES-SCLC Population

      Russ Conroy
      July 15th 2025
      Article

      Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.

      Related Content

      Graphic of a person with tumors in their right lung

      ZEN-3694 Receives FDA Fast Track Status in Metastatic NUT Carcinoma

      Russ Conroy
      July 23rd 2025
      Article

      The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      Photo of a healthcare worker holding an x-ray of lungs with tumors

      Tarlatamab Yields Response in Real-World ES-SCLC Population

      Russ Conroy
      July 15th 2025
      Article

      Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.

      Latest Conference Coverage

      Understanding How On-Target and Off-Target ADC Toxicities Work

      Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers

      Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.